Lupine receives approval from US FDA

Mumbai, May 21 (UNI) Pharma major Lupin Ltd here today reported that it has received tentative approval from US Food and Drug Administration (FDA) for its Abbreviated New drug Application (ANDA) for 'Ziprasidone'capsules, an anti-psychotic drug used in the treatment of schizophrenia and bi-polar disorder.

The company also stated that by receiving the approval on ANDA, there will be limited competition when the product goes generic.

Lupin's Ziprasidone Capsules are AB rated generic equivalent of Pfizer's Geodon capsules used for the same purpose.

Lupin is a leading global player in Anti-TB, Cephalosporins (anti-infectives) and Cardiovascular drugs (prils and statins) and has a notable presence in the areas of diabetology, NSAIDS and Asthma.

UNI